Gossamer Bio’s investment case now centers on seralutinib’s regulatory path after the company submitted a New Drug Application (NDA) for pulmonary arterial hypertension. Analyst views remain sharply ...

This article will be periodically updated with new products and information. This article was updated in October 2026. Tire pressure is one of those things that’s easy to overlook until it makes ...

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in ...

Deanne Gage is a reporter for Globe Advisor at The Globe and Mail. She has specialized in issues pertaining to financial advisors for more than two decades. She is the former editor of FORUM and ...

For a 14th straight month, the overall Rural Mainstreet Index (RMI) sank below growth neutral, according to the October ...

The .gov means it’s official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.